167 related articles for article (PubMed ID: 36164943)
1. Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
Hong JY; Cho HJ; Yun KH; Lee YH; Kim SH; Baek W; Kim SK; Lee Y; Choi YL; Kwon M; Kim HS; Lee J
Cancer Res Treat; 2023 Apr; 55(2):671-683. PubMed ID: 36164943
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS
BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622
[TBL] [Abstract][Full Text] [Related]
5. Gene expression-based prediction of pazopanib efficacy in sarcoma.
Heilig CE; Laßmann A; Mughal SS; Mock A; Pirmann S; Teleanu V; Renner M; Andresen C; Köhler BC; Aybey B; Bauer S; Siveke JT; Hamacher R; Folprecht G; Richter S; Schröck E; Brandts CH; Ahrens M; Hohenberger P; Egerer G; Kindler T; Boerries M; Illert AL; von Bubnoff N; Apostolidis L; Jost PJ; Westphalen CB; Weichert W; Keilholz U; Klauschen F; Beck K; Winter U; Richter D; Möhrmann L; Bitzer M; Schulze-Osthoff K; Brors B; Mechtersheimer G; Kreutzfeldt S; Heining C; Lipka DB; Stenzinger A; Schlenk RF; Horak P; Glimm H; Hübschmann D; Fröhling S
Eur J Cancer; 2022 Sep; 172():107-118. PubMed ID: 35763870
[TBL] [Abstract][Full Text] [Related]
6. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
[TBL] [Abstract][Full Text] [Related]
7. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT
Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662
[TBL] [Abstract][Full Text] [Related]
8. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
Cho HJ; Yun KH; Shin SJ; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Ryu HJ; Lee J; Cho I; Go H; Ko J; Jung I; Jeon MK; Rha SY; Kim HS
Nat Commun; 2024 Jan; 15(1):685. PubMed ID: 38263321
[TBL] [Abstract][Full Text] [Related]
10. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Bupathi M; Hays JL; Chen JL
PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H; Okuma T; Oka H; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Sato K; Abe S; Kawano H; Goto T; Tanaka S
Int J Clin Oncol; 2018 Apr; 23(2):368-374. PubMed ID: 29086877
[TBL] [Abstract][Full Text] [Related]
17. Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
Sharma A; Kataria B; Biswas B; Bakhshi S; Pushpam D
J Oncol Pharm Pract; 2022 Apr; 28(3):560-568. PubMed ID: 33719725
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
van der Graaf WT; Blay JY; Chawla SP; Kim DW; Bui-Nguyen B; Casali PG; Schöffski P; Aglietta M; Staddon AP; Beppu Y; Le Cesne A; Gelderblom H; Judson IR; Araki N; Ouali M; Marreaud S; Hodge R; Dewji MR; Coens C; Demetri GD; Fletcher CD; Dei Tos AP; Hohenberger P; ;
Lancet; 2012 May; 379(9829):1879-86. PubMed ID: 22595799
[TBL] [Abstract][Full Text] [Related]
20. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
